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Background: Diagnosis of choledocholithiasis requires clinical manifestations and imaging examination findings
suggesting a stone in the common bile duct (CBD), but these factors are not highly sensitive or specific. The
choledocholithiasis management algorithm proposed by the American Society for Gastrointestinal Endoscopy
(ASGE) may not be appropriate for patients who fulfill the clinical criteria for a high likelihood of choledocholithiasis.
Endoscopic ultrasonography (EUS) may replace endoscopic retrograde cholangiopancreatography (ERCP) for the
detection of CBD stones in all patients. The aims of this study were to determine the diagnostic yield and optimal
timing of EUS in patients with an intermediate or high likelihood of choledocholithiasis requiring therapeutic ERCP.
Methods: Patients with suspected choledocholithiasis who underwent EUS between June 2009 and January 2012
were retrospectively reviewed. The patients were divided into two groups based on the likelihood of
choledocholithiasis according to the clinical predictors described by the ASGE guidelines: an intermediate likelihood
group and a high likelihood group. The demographic data, clinical manifestations at presentation, blood test results,
EUS and ERCP findings, and clinical manifestations during the follow-up period were recorded and analyzed.
Results: Ninety-three patients were enrolled in the study (52.7% in the intermediate likelihood group and 47.3% in
the high likelihood group). CBD stones were detected in 22.44% of patients in the intermediate likelihood group
and 38.63% of patients in the high likelihood group. EUS had a sensitivity of 100% and specificity of 80% for
detection of CBD stones. An alkaline phosphatase level of >133 mg/dL (area under the curve, 0.576) was the only
factor that was significantly associated with detection of CBD stones in patients who underwent EUS >7 days after
the initial clinical presentation (odds ratio 4.87, p = 0.01).
Conclusions: EUS is an accurate diagnostic tool for the detection of CBD stones, and can prevent the unnecessary
use of ERCP. This study found that use of clinical criteria alone might not provide a good prediction of the
presence of CBD stones, even in patients who fulfill the criteria for a high likelihood of choledocholithiasis.
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Figure 1 Clinical predictors of choledocholithiasis. CBD common
bile duct, US ultrasonography.
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Choledocholithiasis is a common condition, which occurs
in 10–20% of patients with cholelithiasis, 7–14% of pa-
tients who have undergone cholecystectomy, and 18–33%
of patients with acute biliary pancreatitis [1]. Management
of patients with suspected choledocholithiasis requires
confirmation of stones in the common bile duct (CBD).
Diagnosis of choledocholithiasis is based on clinical
signs and symptoms, levels of serum markers of chole-
stasis, and imaging examination findings (transabdom-
inal ultrasonography), but these factors are not highly
sensitive or specific. Endoscopic retrograde cholangio-
pancreatography (ERCP) is the gold standard method for
diagnosis and treatment of choledocholithiasis. However,
as indiscriminate use of ERCP increases the risk of
procedure-related complications [2], ERCP is almost
exclusively reserved for therapeutic purposes, and cho-
ledocholithiasis is usually diagnosed using non-invasive
methods.
The benefits of using endoscopic ultrasonography
(EUS) for the detection of CBD stones were described
by Amouyal et al. in 1989 [3]. EUS is less invasive than
ERCP, and has excellent sensitivity and specificity for the
detection of CBD stones [4,5]. Considering the increas-
ing availability of EUS in hospitals, and recent reports
that EUS may have a higher diagnostic accuracy than
magnetic resonance cholangiopancreatography for the
detection of small CBD stones (<5 mm), EUS should be
recommended for the detection of CBD stones instead
of ERCP, to minimize the risk of procedure-related com-
plications. According to the 2010 American Society for
Gastrointestinal Endoscopy (ASGE) guidelines [6], which
mainly cite the studies by Bakun et al. and Abboud et al.
[7,8], an EUS-guided management algorithm may be
cost-effective for patients with an intermediate risk of
choledocholithiasis, while an ERCP-guided approach
may be more economic in patients with a high risk of
choledocholithiasis. However, we experienced several pa-
tients at our institution who fulfilled the criteria for a
high likelihood of choledocholithiasis and underwent
ERCP, in whom no stones were detected. Ang et al. [9]
reported that CBD stones were detected in only 29.6% of
the 112 patients in their study who fulfilled the criteria
for a high likelihood of CBD stones, which is lower than
previously reported rates [9-13]. We postulate that dis-
crepancies between the likelihood of choledocholithiasis
and the detection of CBD stones on EUS may be related
to the length of time between the initial clinical presen-
tation and the EUS examination, and that ERCP may
not always be more appropriate than EUS in patients
who fulfill the criteria for a high likelihood of chole-
docholithiasis. The aims of this study were to determine
the diagnostic yield and optimal timing of EUS in
patients with an intermediate or high likelihood ofcholedocholithiasis requiring therapeutic ERCP, and to
identify the factors associated with detection of CBD
stones in our endoscopy clinics.
Methods
Study population
This study was approved by the institutional review
board of Siriraj Hospital. Patients who presented with
clinical manifestations suggestive of choledocholithiasis,
who had inconclusive findings on initial imaging exa-
minations and subsequently underwent EUS between
June 2009 and January 2012, were included in the study.
The medical records were retrospectively reviewed and
the demographic data, clinical manifestations at presen-
tation, blood test results, imaging examination findings,
EUS and ERCP findings, and clinical manifestations
during the follow-up period were recorded and analyzed.
Patients were included in the study if they had at least
two of the following clinical manifestations of choledo-
cholithiasis: right upper abdominal or epigastric pain,
jaundice, fever, unexplained derangement of liver func-
tion tests, or abnormal findings on imaging exami-
nations of the hepatobiliary tract such as a dilated CBD
(≥7 mm with an intact gallbladder or ≥10 mm after
cholecystectomy) or a suspected CBD stone. The exclu-
sion criteria were: age <18 years, pregnancy, and inability
to provide informed consent. The patients were divided
into two groups based on based on the likelihood of
choledocholithiasis according to the clinical predictors
described by the ASGE guidelines: an intermediate like-
lihood group and a high likelihood group (Figure 1) [6].
EUS examinations
Patients underwent EUS using a GF-UE160 radial echo-
endoscope (Olympus Corporation, Tokyo, Japan). EUS
was performed by a dedicated endoscopist who was
Table 1 Detection of CBD stones by EUS and ERCP
CBD stone detected
by EUS n (%)
CBD stone detected
by ERCP n (%)
Intermediate likelihood
(n = 49)
11 (22.44%) 11 (22.44%)
High likelihood (n = 44) 18 (40.90%) 17 (38.63%)
CBD common bile duct, EUS endoscopic ultrasonography, ERCP endoscopic
retrograde cholangiopancreatography.
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hospital, where more than 400 EUS procedures are per-
formed annually. EUS was performed under conscious
sedation administered by an anesthesiologist using mid-
azolam, fentanyl, or propofol. The EUS findings were
considered positive if hyperechoic foci were detected in
the CBD, with or without associated acoustic shadows
or biliary sludge. If the EUS findings were positive, pa-
tients underwent ERCP to remove the stones using a
TJF-160VR duodenoscope (Olympus Corporation), by
the same endoscopist as part of the same procedure. If
EUS did not detect CBD stones, patients were followed
up for at least 6 months after the index EUS procedure.
If patients were lost to follow-up before the end of the
6-month follow-up period, their status was assessed by
telephone. Four patients with negative EUS findings
underwent ERCP because the consulting surgeon re-
quired a definitive diagnosis prior to performing lapa-
roscopic cholecystectomy. Positive EUS findings were
only considered truly positive if stones or sludge were
visualized by ERCP. Patients with truly positive findings
underwent sphincterotomy followed by basket or bal-
loon sweeping of the bile duct. Negative EUS findings
were considered truly negative if no stones or sludge
were found during ERCP with balloon sweeping of the
bile duct. A negative outcome associated with an EUS-
based false-negative diagnosis was defined as detection
of CBD stones during the follow-up period associated
with pain thought to be of biliary origin, cholangitis, or
acute pancreatitis. Clinical, blood test, and endoscopic
findings were compared between patients with and with-
out detection of CBD stones.
Statistical analysis
Descriptive data are presented as mean and standard de-
viation (SD). Factors associated with CBD stones were
assessed by univariate analyses using the χ2-test, and by
multivariate logistic regression analysis with calculation
of odds ratios and 95% confidence intervals (CIs). The
sensitivity, specificity, negative predictive value, and po-
sitive predictive value of EUS for detection of CBD
stones were calculated, using the ERCP findings as the
gold standard. All statistical analyses were performed
using SPSS software version 18.0.
Results
Ninety-three patients were included in the study, out of
a total of 914 patients who underwent ERCP for CBD
stone removal between June 2009 and January 2012. The
mean (±SD) age of the patients was 61.0 (±15.6) years
(range, 26–85 years), and 47 (50.5%) were men. The
mean (±SD) time between the initial clinical pre-
sentation and the EUS examination was 37.6 (±56.6)
days (range, 1–420 days). The most common clinicalmanifestations were abdominal pain, jaundice, and fever,
which occurred in 74.2%, 29.0%, and 23.7% of patients,
respectively. Leukocytosis was found in 25.8% of patients.
The bilirubin level was abnormal in 53.2% of patients, and
the mean (±SD) total bilirubin level was 2.9 (±4.4) mg/dL
(range, 0.2–34.8 mg/dL). Abnormal liver enzyme levels
were found in 71.2% of patients. The mean (±SD) se-
rum glutamic-oxaloacetic transaminase level was 169.9
(±206.9) U/L (range, 10–936 U/L), the mean (±SD) serum
glutamic-pyruvic transaminase level was 158.3 (±203.2)
U/L (range, 7–1376 U/L), and the mean (±SD) alkaline
phosphatase level was 174.3 (±156.4) U/mL (range, 36–
885 U/mL). According to the clinical classification criteria
described previously [6], 52.7% of the patients had an
intermediate likelihood of choledocholithiasis and 47.3%
had a high likelihood choledocholithiasis.
EUS found CBD stones in 29 of the 93 patients (31.2%).
Thirty-three patients underwent ERCP on the same day as
their EUS examination, including 29 with CBD stones de-
tected on EUS (28 truly positive) and 4 without CBD
stones detected on EUS (all truly negative). EUS therefore
had a sensitivity of 100% and specificity of 80% for detec-
tion of CBD stones, with a positive predictive value of
96.55% and a negative predictive value of 100%. Patients
who did not have CBD stones detected on EUS were
followed up. The mean (±SD) follow-up period was 10.2
(±7.9) months (range, 1–41 months). Thirty-four patients
(36.6%) were lost to follow-up within 6 months. All the
patients lost to follow-up were contacted by telephone,
and none of them experienced any abdominal pain sus-
picious of biliary colic or underwent ERCP for stone re-
moval at another hospital.
Table 1 shows the EUS and ERCP findings. CBD
stones were detected in 22.44% of patients with an inter-
mediate likelihood of choledocholithiasis and 38.63% of
patients with a high likelihood of choledocholithiasis.
Univariate analyses of the factors potentially asso-
ciated with choledocholithiasis are shown in Table 2. An
elevated alkaline phosphatase level and EUS examin-
ation within 7 days of the initial clinical presentation
were associated with detection of CBD stones.
Subgroup analysis was performed to compare patients
who underwent EUS within 7 days of the initial clinical
presentation and patients who underwent EUS more
than 7 days after the initial clinical presentation. An
Table 2 Univariate analyses of factors potentially associated with detection of CBD stones
No CBD stone detected (n = 65) CBD stone detected (n = 28) p value
Mean (±SD) age (years) 58.85 (±16.09) 65.26 (±13.76) 0.06
Mean (±SD) alkaline phosphatase level (U/mL) 147.40 (±127.55) 226.30 (±192.64) 0.02*
Mean (±SD) total bilirubin level (mg/dL) 3.19 (±5.20) 2.57 (±2.33) 0.54
Mean (±SD) SGOT level (U/L) 215.13 (±176.86) 215.13 (±250.75) 0.13
Mean (±SD) SGPT level (U/L) 137.07 (±210.94) 198.65 (±184.04) 0.17
Clinical classification 0.06
Intermediate likelihood (n = 49) 38 11
High likelihood (n = 44) 27 17
Dilated CBD on transabdominal
ultrasonography (n = 26) 5 21 0.48
Mean (±SD) time interval (days) 38.95 (±62.77) 33.23 (±42.24) 0.64
EUS performed within 7 days (n) 14 14 0.02*
CBD common bile duct, EUS endoscopic ultrasonography, ERCP endoscopic retrograde cholangiopancreatography, SGOT serum glutamic-oxaloacetic transaminase,
SGPT serum glutamic-pyruvic transaminase.
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the curve, 0.576) was the only factor associated with de-
tection of CBD stones in patients who underwent EUS
more than 7 days after the initial clinical presentation
(odds ratio: 4.87, p = 0.01) (Table 3). Additional analyses
of individual or combined choledocholithiasis predictors
that are classified as “strong” or “very strong” in the
ASGE guidelines [6] did not show significant associa-
tions between these factors and the detection of CBD
stones (data not shown).
Discussion
The reported sensitivity and specificity of non-invasive
imaging examinations for the detection of CBD stones
are 25–58% and 68–91%, respectively, for transabdo-
minal ultrasonography; and 87% (95% CI: 84–90) and 97%
(95% CI: 95–98), respectively, for computed tomography
[14]. Magnetic resonance cholangiopancreatography has a
sensitivity of approximately 91% (95% CI: 73–97) for
detection of CBD stones, depending on the stone size as
follows: 67–100% for stones >10 mm, 89–94% for stones
6–10 mm, and 33–71% for stones <6 mm [14]. The opti-
mal initial non-operative investigation for the detection of
CBD stones is therefore still unclear.
Although ERCP is the gold standard method for
detection of CBD stones, with a reported sensitivity of
90% and specificity of 98%, indiscriminate use of ERCPTable 3 Detection of CBD stones in patients with an alkaline
EUS ≤7 days and >7 days after the initial clinical presentation
Alkaline phosphatase level >133 mg/dL and EUS ≤7 days after presentation
Alkaline phosphatase level >133 mg/dL and EUS >7 days after presentation (
CBD common bile duct, EUS endoscopic ultrasonography.results in an increased rate of associated complications.
ERCP is therefore almost exclusively used for the-
rapeutic purposes, with non-invasive tests used for the
detection of CBD stones. EUS is a new, less invasive
imaging technique that has shown very good sensitivity
(95%) and specificity (98%) for the detection of CBD
stones [4,5]. In this study, EUS detected CBD stones in
all the patients who were truly positive for CBD stones,
with only one false-positive case. Retrospective review of
the EUS images from the false-positive case showed a
suspected echo artifact. EUS should be the imaging
examination of choice for the detection of CBD stones,
because of its high sensitivity and specificity. EUS is as
effective as ERCP for detecting CBD stones, and has
fewer procedural risks and complications. However, EUS
also has some disadvantages, including the high cost, the
need for expertise in the procedure, and the lack of
availability in some hospitals.
The present study included almost equal numbers of
patients with intermediate and high likelihood of cho-
ledocholithiasis. CBD stones were detected in 22.44% of
patients in the intermediate likelihood group and 38.63%
of patients in the high likelihood group. These results
differ from previous studies, which reported detection of
CBD stones in up to 40% of patients in the intermediate
likelihood group and 60% of patients in the high like-
lihood group [10-15]. We postulate that the lower ratephosphatase level >133 mg/dL, who underwent
No CBD stone
detected (n = 65)
CBD stone
detected (n = 28)
p value
(n = 17) 7 10 0.29
n = 25) 14 11 0.01*
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taneous passage of the stones, which is reported to occur
at a rate of 20% per week [16], and would be affected by
the time between the initial clinical presentation and the
EUS examination. Our findings therefore support the
potential cost-effectiveness of EUS for patients with an
intermediate likelihood of choledocholithiasis suggested
by the ASGE algorithm, and the performance of EUS-
guided ERCP. However, routine ERCP may not be
appropriate for all patients with a high likelihood of
choledocholithiasis.
In the past decade, many studies have demonstrated
that EUS is as accurate as ERCP for the detection of
CBD stones, and that EUS is associated with fewer com-
plications than ERCP [17-22]. However, EUS is not avail-
able in all hospitals, especially in developing countries.
Currently, EUS is only available in large tertiary hospi-
tals, which may result in delay between the initial clinical
presentation and the EUS examination. In the current
study, patients who underwent EUS within 7 days of the
initial presentation were more likely to have positive
findings than patients who underwent EUS more than
7 days after the initial clinical presentation. Our analyses
show that EUS more than 7 days after the initial clinical
presentation and an elevated alkaline phosphatase level
were associated with detection of CBD stones, especially
when the alkaline phosphatase level was >133 mg/dL.
This study was limited by its retrospective design and
the relatively small number of patients. The results are
therefore only applicable to similar healthcare situations.
Further prospective studies should be conducted to con-
firm the findings of this study.Conclusions
EUS is an accurate diagnostic tool for the detection of
CBD stones, and can reduce the unnecessary use of
ERCP. This study demonstrated that use of clinical cri-
teria alone might not provide good predictions regarding
the presence of CBD stones in all patients, even those
who fulfill the criteria for a high likelihood of choledo-
cholithiasis. EUS examination should be considered for
patients with a high likelihood of choledocholithiasis,
especially those who cannot undergo ERCP within 7 days
of the initial clinical presentation or who have a high
risk of ERCP-related complications, to minimize un-
necessary ERCP procedures.Abbreviations
ASGE: American society for gastrointestinal endoscopy; CBD: Common bile duct;
CI: Confidence interval; ERCP: Endoscopic retrograde cholangiopancreatography;
EUS: Endoscopic ultrasonography; SD: Standard deviation.Competing interests
The authors declare that they have no competing interest.Authors’ contributions
VP conceived and designed the study. PB, MD and AP acquired the data.
VP and PA wrote and revised the paper and incorporated important
intellectual content. All authors read and proved the final manuscript.Acknowledgments
We are grateful to Dr Nonthalee Pausawasdi and Dr Supot Pongprasobchai
for allowing inclusion of their patients in the study.Funding
No funding was received for this study.
Author details
1Department of Internal Medicine, Siriraj GI Endoscopy Center, Siriraj Hospital,
Division of Gastroenterology, Faculty of Medicine, Mahidol University,
Bangkok, Thailand. 2Liver and Digestive Institute, Samitivej Sukhumvit
Hospital, Bangkok, Thailand. 3Department of Medicine, Patommatat
Bhunthumkomol, Gastrointestinal Unit, Thammasat University Hospital,
Pathumthani 12120, Thailand.
Received: 17 April 2014 Accepted: 24 September 2014
Published: 26 September 2014References
1. Freitas ML, Bell RL, Duffy AJ: Choledocholithiasis: evolving standards for
diagnosis and management. World J Gastroenterol 2006, 12:3162–3167.
2. Petrov MS, Savides TJ: Systematic review of endoscopic ultrasonography
versus endoscopic retrograde cholangiopancreatography for suspected
choledocholithiasis. Br J Surg 2009, 96:967–974.
3. Amouyal P, Palazzo L, Amouyal G, Ponsot P, Mompoint D, Vilgrain V,
Gayet B, Fléjou JF, Paolaggi JA: Endosonography: promising method for
diagnosis of extrahepatic cholestasis. Lancet 1989, 2:1195–1195.
4. Garrow D, Miller S, Sinha D, Conway J, Hoffman BJ, Hawes RH, Romagnuolo
J: Endoscopic ultrasound: a meta-analysis of test performance in
suspected biliary obstruction. Clin Gastroenterol Hepatol 2007, 5:616–623.
5. Tse F, Liu L, Barkun AN, Armstrong D, Moayyedi P: EUS: a meta-analysis of
test performance in suspected choledocholithiasis. Gastrointest Endosc
2008, 67:235–244.
6. ASGE Standards of Practice Committee, Maple JT, Ben-Menachem T,
Anderson MA, Appalaneni V, Banerjee S, Cash BD, Fisher L, Harrison ME,
Fanelli RD, Fukami N, Ikenberry SO, Jain R, Khan K, Krinsky ML, Strohmeyer L,
Dominitz JA: The role of endoscopy in the evaluation of suspected
choledocholithiasis. Gastrointest Endosc 2010, 71:1–9.
7. Barkun AN, Barkun JS, Fried GM, Ghitulescu G, Steinmetz O, Pham C,
Meakins JL, Goresky CA: Useful predictors of bile duct stones in patients
undergoing laparoscopic cholecystectomy. McGill Gallstone Treatment
Group. Ann Surg 1994, 220:32–39.
8. Abboud PAC, Malet PF, Berlin JA, Staroscik R, Cabana MD, Clarke JR, Shea
JA, Schwartz JS, Williams SV: Predictors of common bile duct stones prior
to cholecystectomy: a meta-analysis. Gastrointest Endosc 1996, 44:450–455.
9. Ang TL, Liew SFAP, Ang D, Kwek A, Fock KM, Teo EK: EUS-guided ERCP in
patients with negative cross sectional imaging but high clinical
probability of choledocholithiasis. Gastrointest Endosc 2012, 75:AB203.
10. Polkowski M, Regula J, Tilszer A, Butruk E: Endoscopic ultrasound versus
endoscopic retrograde cholangiography for patients with intermediate
probability of bile duct stones: a randomized trial comparing two
management strategies. Endoscopy 2007, 39:296–303.
11. Lee YT, Chan FKL, Leung WK, Chan HL, Wu JC, Yung MY, Ng EK, Lau JY,
Sung JJ: Comparison of EUS and ERCP in the investigation with
suspected biliary obstruction caused by choledocholithiasis:
a randomized study. Gastrointest Endosc 2008, 67:660–668.
12. Karakan T, Cindoruk M, Alagozlu H, Ergun M, Dumlu S, Unal S: EUS versus
endoscopic retrograde cholangiography for patients with intermediate
probability of bile duct stones: a prospective randomized trial.
Gastrointest Endosc 2009, 69:244–252.
13. Benjaminov F, Stein A, Lichtman G, Pomeranz I, Konikoff FM: Consecutive
versus separate session of endoscopic ultrasound (EUS) and endoscopic
retrograde cholangiopancreatography (ERCP) for symptomatic
choledocholithiasis. Surg Endosc 2013, 27:2117–2121.
Prachayakul et al. BMC Gastroenterology 2014, 14:165 Page 6 of 6
http://www.biomedcentral.com/1471-230X/14/16514. Tse F, Barkun JS, Romagnuolo J, Friedman G, Bornstein JD, Barkun AN:
Nonoperative imaging techniques in suspected biliary tract obstruction.
HPB (Oxford) 2006, 8:409–425.
15. Malik S, Kaushik N, Khalid A, Bauer K, Brody D, Slivka A, McGrath K: EUS
yield in evaluating biliary dilatation in patients with normal serum liver
enzymes. Dig Dis Sci 2007, 52:508–512.
16. Frossard JL, Hadengue A, Amouyal G, Choury A, Marty O, Giostra E,
Sivignon F, Sosa L, Amouyal P: Choledocholithiasis: a prospective study of
spontaneous common bile duct stone migration. Gastrointest Endosc
2000, 51:175–179.
17. Lisi SD, Leandro G, Buscarini E: Endoscopic ultrasonography versus
endoscopic retrograde cholangiopancreatography in acute biliary
pancreatitis: a systematic review. Eur J Gastroenterol Hepatol 2011,
23:367–374.
18. Napoléon B, Dumortier J, Keriven-Souquet O, Pujol B, Ponchon T, Souquet
JC: Do normal finding at biliary endoscopic ultrasonography obviate the
need for endoscopic retrograde cholangiography in patients with
suspicion of common bile duct stone? A prospective follow-up study of
238 patients. Endoscopy 2003, 35:411–415.
19. Chan HH, Wang EM, Sun MS, Hsu PI, Tsai WL, Tsai TJ, Wang KM, Chen WC,
Liang HL, Lai KH, Brugge WR: Linear echoscope-guided ERCP for the
diagnosis of occult common bile duct stones. BMC Gastroenterol 2013,
13:13–44.
20. Caerriere V, Conway J, Evans J, Shokoohi S, Mishra G: Which patients with
dilated common bile and/or pancreatic ducts have positive findings on
EUS? J Interv Gastroenterol 2012, 2:168–171.
21. Cui ML, Cho JH, Kim TN: Long-term follow-up study of gallbladder in situ
after endoscopic common duct stone removal in Korean patients.
Surg Endosc 2013, 27:1711–1716.
22. da Silveira EB, Barkun AN: EUS-first versus ERC-first for patients with
intermediate probability of bile duct stones: is one strategy superior to
the other? Endoscopy 2007, 39:357–358.
doi:10.1186/1471-230X-14-165
Cite this article as: Prachayakul et al.: Diagnostic yield of endoscopic
ultrasonography in patients with intermediate or high likelihood of
choledocholithiasis: a retrospective study from one university-based
endoscopy center. BMC Gastroenterology 2014 14:165.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
